[P68] Poster Session 68　Clinical Trial Facilitation Program

[P68-3] Phase2 study comparing the efficacy between afatinib & osimertinib based on immunological biomarker in EGFR-mutant NSCLC

^○Kei Morikawa¹, Hisashi Tanaka², Saori Takata³, Satoshi Watanabe⁴, Kazuma Kishi⁵, Kenzo Soejima⁶, Kyoichi Kaira⁷, Hiroshi Kagamu⁷, Kenichi Yoshimura⁸, Noriyuki Matsutani⁹, Nobuhiko Seki¹⁰ (1.Division of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine, 2.Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, 3.Department of Respiratory Medicine, Kyorin University School of Medicine, 4.Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, 5.Department of Respiratory Medicine, Toho University Omori Medical Center, 6.Clinical and Translational Research Center, Keio University Hospital, 7.Department of Respiratory Medicine, Saitama Medical University International Medical Center, 8.Medical Center for Translational and Clinical Research, Hiroshima University Hospital, 9.Department of Surgery, Teikyo University Hospital, Mizonokuchi, 10.Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine)